Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatitis C Virus Infection
100%
Sustained Virological Response
100%
Monitoring Approach
100%
Minimal Monitoring
100%
Single-arm Trial
100%
Treatment Initiation
50%
Hepatitis C Virus RNA
50%
Serious Adverse Events
50%
Safety Analysis
50%
Sofosbuvir
50%
Primary Safety
50%
Unplanned Hospital Visits
50%
Hepatitis C Virus Treatment
50%
Hepatitis C Virus
25%
Diagnostic Test
25%
Fixed-dose Combination
25%
Uganda
25%
South Africa
25%
Brazil
25%
Treatment-related
25%
Two-point
25%
Thailand
25%
Outcome Assessment
25%
Safety Outcomes
25%
Treatment Response
25%
Exclusion Criteria
25%
Once-daily
25%
Treatment Discontinuation
25%
World Population
25%
Limit of Quantification
25%
Treatment Course
25%
Treatment Assessment
25%
Response Assessment
25%
Direct-acting Antivirals
25%
Barriers to Treatment
25%
Laboratory Monitoring
25%
Healthcare Infrastructure
25%
U.S. National Institutes of Health
25%
Treatment-naïve
25%
Efficacy Analysis
25%
Decompensated Cirrhosis
25%
Generic Formulation
25%
Frequent Visits
25%
Gilead
25%
Monitoring Test
25%
Treatment Scale
25%
Old Evidence
25%
Hepatitis C Virus Elimination
25%
World Data
25%
During Treatment
25%
Efficacy Outcomes
25%
Remote Contact
25%
Treatment Period
25%
HIV/hepatitis C Virus Coinfection
25%
Medicine and Dentistry
Arm
100%
Hepatitis C
100%
Hepatitis C Virus
100%
Adverse Event
28%
Virus RNA
28%
Liver Cirrhosis
14%
Health Care
14%
Human Immunodeficiency Virus
14%
Treatment Response
14%
Outcome Assessment
14%
Mixed Infection
14%
Case Finding
14%
Viral Clearance
14%
Antiviral Drug
14%
Sofosbuvir
14%
Velpatasvir
14%
Oral
14%
Real-World Data
14%
Republic of South Africa
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C
100%
Hepatitis C Virus
100%
Adverse Event
28%
Virus RNA
28%
HIV
14%
Sofosbuvir
14%
Tablet
14%
Liver Cirrhosis
14%
Viral Clearance
14%
Mixed Infection
14%
Antiviral Drug
14%
Velpatasvir
14%